Literature DB >> 22610613

Predicting methicillin resistance among community-onset Staphylococcus aureus bacteremia patients with prior healthcare-associated exposure.

S-Y Chen1, W-C Chiang, M H-M Ma, P-R Hsueh, S-C Chang, C-C Fang, S-C Chen, W-J Chen, W-C Chie, M-S Lai.   

Abstract

To develop and validate prediction rules to identify the risk of methicillin-resistant Staphylococcus aureus (MRSA) infection among community patients who have healthcare-associated (HA) exposure and S. aureus bacteremia. A total of 1,166 adults with community-onset S. aureus bacteremia were retrospectively enrolled. The background prevalence of community MRSA infection was extrapolated from 392 community-associated S. aureus bacteremia (CA-SAB) patients without HA exposure. Complete and clinical risk scores were derived and tested using data from 774 healthcare-associated S. aureus bacteremia (HA-SAB) patients. The risk scores were modeled with and without incorporating previous microbiological data as a model predictor and stratified patients to low-, intermediate-, and high-risk groups for MRSA infection. The clinical risk score included five independent predictors and the complete risk score included six independent predictors. The clinical and complete risk scores stratified 32.7 % and 42.0 % of HA-SAB patients to the low-risk group for MRSA infection respectively. The prevalence of MRSA infection in score-stratified low-risk groups ranged from 16.3 % to 23.3 %, comparable to that of CA-SAB patients (13.8 %). Simple decision rules allow physicians to stratify the risk of MRSA infection when treating community patients with prior HA exposure and possible S. aureus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610613     DOI: 10.1007/s10096-012-1621-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

1.  Duration of colonization by methicillin-resistant Staphylococcus aureus after hospital discharge and risk factors for prolonged carriage.

Authors:  A Scanvic; L Denic; S Gaillon; P Giry; A Andremont; J C Lucet
Journal:  Clin Infect Dis       Date:  2001-04-20       Impact factor: 9.079

2.  Origins of community strains of methicillin-resistant Staphylococcus aureus.

Authors:  Edwin D Charlebois; Françoise Perdreau-Remington; Barry Kreiswirth; David R Bangsberg; Daniel Ciccarone; Binh A Diep; Valerie L Ng; Kimberly Chansky; Brian R Edlin; Brian Edlin; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-06-01       Impact factor: 9.079

Review 3.  Clinical prediction rules. A review and suggested modifications of methodological standards.

Authors:  A Laupacis; N Sekar; I G Stiell
Journal:  JAMA       Date:  1997-02-12       Impact factor: 56.272

4.  Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.

Authors:  Andrew F Shorr; Marya D Zilberberg; Richard Reichley; Jason Kan; Alex Hoban; Justin Hoffman; Scott T Micek; Marin H Kollef
Journal:  Clin Infect Dis       Date:  2011-11-21       Impact factor: 9.079

5.  Characteristics of community-acquired and health care-associated Staphylococcus aureus bacteremia in patients treated at the emergency department of a teaching hospital.

Authors:  Chun-Hsing Liao; Shey-Ying Chen; Shan-Chwen Chang; Po-Ren Hsueh; Chien-Ching Hung; Yee-Chun Chen
Journal:  Diagn Microbiol Infect Dis       Date:  2005-09-15       Impact factor: 2.803

6.  Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia.

Authors:  Yardena Siegman-Igra; Boaz Fourer; Ruth Orni-Wasserlauf; Yoav Golan; Aliza Noy; David Schwartz; Michael Giladi
Journal:  Clin Infect Dis       Date:  2002-04-30       Impact factor: 9.079

7.  Impact of traditional hospital strain of methicillin-resistant Staphylococcus aureus (MRSA) and community strain of MRSA on mortality in patients with community-onset S aureus bacteremia.

Authors:  Shey-Ying Chen; Jann-Tay Wang; Tony Hsiu-Hsi Chen; Mei-Shu Lai; Wei-Chu Chie; Kuo-Liong Chien; Po-Ren Hsueh; Jiun-Ling Wang; Shan-Chwen Chang
Journal:  Medicine (Baltimore)       Date:  2010-09       Impact factor: 1.889

8.  Adult methicillin-resistant Staphylococcus aureus bacteremia in Taiwan: clinical significance of non-multi-resistant antibiogram and Panton-Valentine leukocidin gene.

Authors:  Jiun-Ling Wang; Jann-Tay Wang; Shey-Ying Chen; Po-Ren Hsueh; Hsiang-Chi Kung; Yee-Chun Chen; Shan-Chwen Chang
Journal:  Diagn Microbiol Infect Dis       Date:  2007-09-18       Impact factor: 2.803

9.  Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.

Authors:  Satish K Pillai; Christine Wennersten; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Adolf W Karchmer
Journal:  Clin Infect Dis       Date:  2009-10-15       Impact factor: 9.079

10.  Outcome and attributable mortality in critically Ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus.

Authors:  Stijn I Blot; Koenraad H Vandewoude; Eric A Hoste; Francis A Colardyn
Journal:  Arch Intern Med       Date:  2002-10-28
View more
  2 in total

1.  Available, Bed-sided, Comprehensive (ABC) score to a diagnosis of Methicillin-resistant Staphylococcus aureus infection: a derivation and validation study.

Authors:  Nori Yoshioka; Matsuo Deguchi; Hideharu Hagiya; Hisao Yoshida; Norihisa Yamamoto; Shoji Hashimoto; Yukihiro Akeda; Kazunori Tomono
Journal:  BMC Infect Dis       Date:  2018-01-08       Impact factor: 3.090

2.  Clinical and epidemiological factors associated with methicillin resistance in community-onset invasive Staphylococcus aureus infections: prospective multicenter cross-sectional study in Korea.

Authors:  Eu Suk Kim; Hong Bin Kim; Gayeon Kim; Kye-Hyung Kim; Kyung-Hwa Park; Shinwon Lee; Young Hwa Choi; Jongyoun Yi; Chung Jong Kim; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam-Joong Kim; Yeong-Seon Lee; Myoung-Don Oh
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.